https://www.jpost.com/opinion/2020-hindsight-israels-year-in-review-653213
As of Tuesday night, when the Knesset voted against the bill to postpone the budget, Israel began the countdown to its fourth general election in two years. Some pundits are pointing to this as a sign of political dysfunction. Others are hailing it as democracy in action. But everyone has been noting the “here we go again” aspect of the ongoing fray.
That the news coincided with a sharp spike in coronavirus morbidity, along with threats and then an announcement of another countrywide lockdown, only made matters worse for national morale. A third round of closures that demolishes small businesses and keeps kids at home is the last thing Israelis want. The latest warnings about the COVID-19 mutation, a few cases of which have arrived in Israel from Britain, further contributed to societal malaise.
The only silver lining, if you can call it that, has been the plethora of humorous coronavirus-spurred memes from around the world about everything from the hoarding of toilet paper to Zoom meetings in which participants are only dressed from the waist up.
Misery loves company, and in Israel as elsewhere, the consensus has been that 2020 is the “year that wasn’t.” A review of the past 12 months, however, reveals that this is far from the case, certainly where the Jewish state is concerned. Working our way backwards can provide a bit of perspective.
Let’s start with December. On December 9, Prime Minister Benjamin Netanyahu was at Ben-Gurion Airport welcoming the arrival of a plane bearing the first shipment of Pfizer’s COVID-19 vaccine. This was the culmination of a $237.5 million deal that he had inked in November with the pharmaceutical giant, for the purchase of eight million doses, sufficient to inoculate nearly half the country’s population. This batch is only the beginning. The prime minister also signed a deal with Moderna for six million doses, enough to vaccinate another three million Israelis. Meanwhile, Israel’s own Institute for Biological Research vaccine, BriLife, is in the midst of advanced clinical trials.